A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation
In current guidelines, the role of immune checkpoint inhibitors is not yet determined in the treatment strategy for NSCLC harboring ALK translocations. A 51-year-old woman with lung adenocarcinoma harboring ALK translocation was treated with alectinib until PD. After the second (CDDP/PEM) and third...
Gespeichert in:
| Veröffentlicht in: | Respiratory investigation 2018-07, Vol.56 (4), p.365-368 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368 |
|---|---|
| container_issue | 4 |
| container_start_page | 365 |
| container_title | Respiratory investigation |
| container_volume | 56 |
| creator | Shimada, Masahiro Tamura, Atsuhisa Yokosuka, Kyoko Kusaka, Kei Matsui, Hirotoshi Nagai, Hideaki Ohta, Ken |
| description | In current guidelines, the role of immune checkpoint inhibitors is not yet determined in the treatment strategy for NSCLC harboring ALK translocations.
A 51-year-old woman with lung adenocarcinoma harboring ALK translocation was treated with alectinib until PD. After the second (CDDP/PEM) and third (crizotinib) line treatment, a second biopsy was performed, revealing PD-L1 tumor proportion score of 70–80% and G1202R mutation of ALK. Pembrolizumab was selected for the fourth line, leading to PR for more than 6 months.
While alectinib might induce resistance to ALK-TKI, it could increase PD-L1 positive cells to become sensitive to PD-1/PD-L1 inhibitors. |
| doi_str_mv | 10.1016/j.resinv.2018.04.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2070792163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S221253451830090X</els_id><sourcerecordid>2070792163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-a7e6cbd28e95469bf6d3d9096f6e3681ac0efb3ebb1d627f9484306f1bc36ce3</originalsourceid><addsrcrecordid>eNp9UUuLFDEQDqK4y7r_QCRHL93m1ZnuizAsui47IMjcQ5KuSIZOZ8xjQe_-bzPMuuxp61JV1PfV60PoPSU9JVR-OvQJsl8fekbo2BPREyJeoUvGKOsGPvDXT7EYLtB1zgfSTA5MUPkWXfCWjGySl-jvFudqLeTs6oKPEEyKi_9Tgza4JNAlwFqw1RlwdHip60-sZ1ij1cn6NQaNtSuQsAEbg2_V01656EYqEW93993-_u5Zp7nCqXBLGWE_cKhFFx_Xd-iN00uG60d_hfZfv-xvvnW777d3N9tdZ_koS6c3IK2Z2QjTIORknJz5PJFJOglcjlRbAs5wMIbOkm3cJEbBiXTUWC4t8Cv08dz2mOKvCrmo4LOFZdErxJoVIxuymRiVvEHFGWpTzDmBU8fkg06_FSXqJIE6qLME6iSBIkI1CRrtw-OEagLMT6T_D2-Az2cAtDMfPCSVrYfVwuwT2KLm6F-e8A8-YJsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2070792163</pqid></control><display><type>article</type><title>A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation</title><source>Alma/SFX Local Collection</source><creator>Shimada, Masahiro ; Tamura, Atsuhisa ; Yokosuka, Kyoko ; Kusaka, Kei ; Matsui, Hirotoshi ; Nagai, Hideaki ; Ohta, Ken</creator><creatorcontrib>Shimada, Masahiro ; Tamura, Atsuhisa ; Yokosuka, Kyoko ; Kusaka, Kei ; Matsui, Hirotoshi ; Nagai, Hideaki ; Ohta, Ken</creatorcontrib><description>In current guidelines, the role of immune checkpoint inhibitors is not yet determined in the treatment strategy for NSCLC harboring ALK translocations.
A 51-year-old woman with lung adenocarcinoma harboring ALK translocation was treated with alectinib until PD. After the second (CDDP/PEM) and third (crizotinib) line treatment, a second biopsy was performed, revealing PD-L1 tumor proportion score of 70–80% and G1202R mutation of ALK. Pembrolizumab was selected for the fourth line, leading to PR for more than 6 months.
While alectinib might induce resistance to ALK-TKI, it could increase PD-L1 positive cells to become sensitive to PD-1/PD-L1 inhibitors.</description><identifier>ISSN: 2212-5345</identifier><identifier>EISSN: 2212-5353</identifier><identifier>DOI: 10.1016/j.resinv.2018.04.004</identifier><identifier>PMID: 30008296</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>ALK-TKI ; G1202R ; PD-1/PD-L1 ; Pembrolizumab ; Precision medicine</subject><ispartof>Respiratory investigation, 2018-07, Vol.56 (4), p.365-368</ispartof><rights>2018 The Japanese Respiratory Society</rights><rights>Copyright © 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-a7e6cbd28e95469bf6d3d9096f6e3681ac0efb3ebb1d627f9484306f1bc36ce3</citedby><cites>FETCH-LOGICAL-c386t-a7e6cbd28e95469bf6d3d9096f6e3681ac0efb3ebb1d627f9484306f1bc36ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30008296$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimada, Masahiro</creatorcontrib><creatorcontrib>Tamura, Atsuhisa</creatorcontrib><creatorcontrib>Yokosuka, Kyoko</creatorcontrib><creatorcontrib>Kusaka, Kei</creatorcontrib><creatorcontrib>Matsui, Hirotoshi</creatorcontrib><creatorcontrib>Nagai, Hideaki</creatorcontrib><creatorcontrib>Ohta, Ken</creatorcontrib><title>A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation</title><title>Respiratory investigation</title><addtitle>Respir Investig</addtitle><description>In current guidelines, the role of immune checkpoint inhibitors is not yet determined in the treatment strategy for NSCLC harboring ALK translocations.
A 51-year-old woman with lung adenocarcinoma harboring ALK translocation was treated with alectinib until PD. After the second (CDDP/PEM) and third (crizotinib) line treatment, a second biopsy was performed, revealing PD-L1 tumor proportion score of 70–80% and G1202R mutation of ALK. Pembrolizumab was selected for the fourth line, leading to PR for more than 6 months.
While alectinib might induce resistance to ALK-TKI, it could increase PD-L1 positive cells to become sensitive to PD-1/PD-L1 inhibitors.</description><subject>ALK-TKI</subject><subject>G1202R</subject><subject>PD-1/PD-L1</subject><subject>Pembrolizumab</subject><subject>Precision medicine</subject><issn>2212-5345</issn><issn>2212-5353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UUuLFDEQDqK4y7r_QCRHL93m1ZnuizAsui47IMjcQ5KuSIZOZ8xjQe_-bzPMuuxp61JV1PfV60PoPSU9JVR-OvQJsl8fekbo2BPREyJeoUvGKOsGPvDXT7EYLtB1zgfSTA5MUPkWXfCWjGySl-jvFudqLeTs6oKPEEyKi_9Tgza4JNAlwFqw1RlwdHip60-sZ1ij1cn6NQaNtSuQsAEbg2_V01656EYqEW93993-_u5Zp7nCqXBLGWE_cKhFFx_Xd-iN00uG60d_hfZfv-xvvnW777d3N9tdZ_koS6c3IK2Z2QjTIORknJz5PJFJOglcjlRbAs5wMIbOkm3cJEbBiXTUWC4t8Cv08dz2mOKvCrmo4LOFZdErxJoVIxuymRiVvEHFGWpTzDmBU8fkg06_FSXqJIE6qLME6iSBIkI1CRrtw-OEagLMT6T_D2-Az2cAtDMfPCSVrYfVwuwT2KLm6F-e8A8-YJsw</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Shimada, Masahiro</creator><creator>Tamura, Atsuhisa</creator><creator>Yokosuka, Kyoko</creator><creator>Kusaka, Kei</creator><creator>Matsui, Hirotoshi</creator><creator>Nagai, Hideaki</creator><creator>Ohta, Ken</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201807</creationdate><title>A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation</title><author>Shimada, Masahiro ; Tamura, Atsuhisa ; Yokosuka, Kyoko ; Kusaka, Kei ; Matsui, Hirotoshi ; Nagai, Hideaki ; Ohta, Ken</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-a7e6cbd28e95469bf6d3d9096f6e3681ac0efb3ebb1d627f9484306f1bc36ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>ALK-TKI</topic><topic>G1202R</topic><topic>PD-1/PD-L1</topic><topic>Pembrolizumab</topic><topic>Precision medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimada, Masahiro</creatorcontrib><creatorcontrib>Tamura, Atsuhisa</creatorcontrib><creatorcontrib>Yokosuka, Kyoko</creatorcontrib><creatorcontrib>Kusaka, Kei</creatorcontrib><creatorcontrib>Matsui, Hirotoshi</creatorcontrib><creatorcontrib>Nagai, Hideaki</creatorcontrib><creatorcontrib>Ohta, Ken</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimada, Masahiro</au><au>Tamura, Atsuhisa</au><au>Yokosuka, Kyoko</au><au>Kusaka, Kei</au><au>Matsui, Hirotoshi</au><au>Nagai, Hideaki</au><au>Ohta, Ken</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation</atitle><jtitle>Respiratory investigation</jtitle><addtitle>Respir Investig</addtitle><date>2018-07</date><risdate>2018</risdate><volume>56</volume><issue>4</issue><spage>365</spage><epage>368</epage><pages>365-368</pages><issn>2212-5345</issn><eissn>2212-5353</eissn><abstract>In current guidelines, the role of immune checkpoint inhibitors is not yet determined in the treatment strategy for NSCLC harboring ALK translocations.
A 51-year-old woman with lung adenocarcinoma harboring ALK translocation was treated with alectinib until PD. After the second (CDDP/PEM) and third (crizotinib) line treatment, a second biopsy was performed, revealing PD-L1 tumor proportion score of 70–80% and G1202R mutation of ALK. Pembrolizumab was selected for the fourth line, leading to PR for more than 6 months.
While alectinib might induce resistance to ALK-TKI, it could increase PD-L1 positive cells to become sensitive to PD-1/PD-L1 inhibitors.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30008296</pmid><doi>10.1016/j.resinv.2018.04.004</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2212-5345 |
| ispartof | Respiratory investigation, 2018-07, Vol.56 (4), p.365-368 |
| issn | 2212-5345 2212-5353 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2070792163 |
| source | Alma/SFX Local Collection |
| subjects | ALK-TKI G1202R PD-1/PD-L1 Pembrolizumab Precision medicine |
| title | A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T20%3A00%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20successful%20pembrolizumab%20treatment%20case%20of%20lung%20adenocarcinoma%20after%20becoming%20resistant%20to%20ALK-TKI%20treatment%20due%20to%20G1202R%20mutation&rft.jtitle=Respiratory%20investigation&rft.au=Shimada,%20Masahiro&rft.date=2018-07&rft.volume=56&rft.issue=4&rft.spage=365&rft.epage=368&rft.pages=365-368&rft.issn=2212-5345&rft.eissn=2212-5353&rft_id=info:doi/10.1016/j.resinv.2018.04.004&rft_dat=%3Cproquest_cross%3E2070792163%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2070792163&rft_id=info:pmid/30008296&rft_els_id=S221253451830090X&rfr_iscdi=true |